GlassScriptPhysician profile
Ebrahim Sajedi
NPI 1154342269
$4,462.52
in general payments reported to CMS, 2019-2025
37 companies · $833 in 2025
The $833 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $40.94 · 2021: $327 · 2022: $349 · 2023: $1,185 · 2024: $1,287 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266 · Education: $38.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,266.46 |
| Education | $38.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $602.24 | 2019-2025 | Repatha, Otezla, Tezspire |
| Novo Nordisk INC | $394.93 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $357.80 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $327.54 | 2021-2025 | |
| Lilly USA, LLC | $285.47 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Regeneron Healthcare Solutions, INC. | $279.07 | 2023-2025 | Dupixent, Evkeeza |
| Shield Therapeutics INC | $271.68 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $234.87 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Abbvie INC. | $234.45 | 2019-2025 | Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $186.25 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Pfizer INC. | $170.88 | 2023-2025 | |
| Dexcom, INC. | $137.37 | 2022-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $137.19 | 2021-2022 | |
| Genzyme Corporation | $107.47 | 2023-2025 | |
| Ardelyx, INC. | $98.29 | 2024-2025 | Ibsrela |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebrahim Sajedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.